LPCAT1 and neoplasm: Additionally, data indicate that LPCAT1 expression levels were generally higher in patients in the immunotherapy response group across multiple immunotherapy cohorts in the Tumor Immune Dysfunction and Exclusion (TIDE) dataset [13].